SEOM warns of pending challenges in prevention and early detection of lung cancer

The SEOM highlights advances in immunotherapy and precision medicine in lung cancer, but warns of challenges in prevention and early diagnosis.

fotonoticia 20261116133446 1920

fotonoticia 20261116133446 1920

Add DEMÓCRATA to Google

Ask FREN

Published

2 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 16 institutos

  • PP31,4 %
  • PSOE27,1 %
  • Vox18,9 %
  • Frente Amplio6,4 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

ELECCIONES 29N

¿Cuál es tu pronóstico? 29N

Reparte los 350 escaños del Congreso como creas que quedarán el 29 de noviembre. Puedes cambiar tu pronóstico hasta que cierren los colegios.

0 de 350 escaños

PP
PSOE
Vox
Frente Amplio
ERC
Junts
EH Bildu
PNV
Más partidos
Podemos
BNG
SALF
CC
UPN
Adelante
Aliança
Otros

Protegido por reCAPTCHA de Google: privacidad y condiciones

Pronóstico de DemócrataParticipación abierta, no es una encuesta

The Spanish Society of Medical Oncology (SEOM) has pointed out that, despite the advances achieved in the treatment of lung cancer, "major challenges" still persist in key areas such as prevention, early diagnosis, equality in access to innovations, and research into new therapeutic options.

SEOM reminds that screening programs with low-dose computed tomography have proven their effectiveness by decreasing lung cancer–specific mortality in people at high risk, defined mainly by age and smoking history.

"Its organized implementation with appropriate selection criteria, quality control, and specific care pathways could allow diagnosing a greater number of tumors in stages that may be curable," the scientific society has said.

Coinciding with World Lung Cancer Day, which is commemorated on November 17, SEOM has highlighted some of the recent milestones in tackling this disease. Among them, it stands out for the introduction of immunotherapy in earlier stages of non-small-cell lung cancer.

"Its administration before surgery, in combination with chemotherapy, or through perioperative strategies that include treatment before and after the intervention, has been shown to increase rates of complete pathological response and reduce the risk of relapse in selected patients," it has explained.

The organization has also emphasized that the detection of specific molecular alterations has made it possible to develop targeted therapies against targets involved in the growth and expansion of tumor cells. "To the initial advances in patients with alterations in EGFR, ALK, ROS1, and RET, options against other targets, such as MET, BRAF, HER2, NTRK, and KRAS, have been added," it added.

In this context, it has reiterated that, in advanced disease, precision medicine continues to progress toward combinations and "more effective" drugs, in addition to strategies focused on specific mechanisms of resistance. According to the entity, in patients with lung cancer with EGFR mutations, regimens such as osimertinib combined with chemotherapy or amivantamab combined with lazertinib have expanded therapeutic alternatives in first line.

On the other hand, SEOM has indicated that small cell lung cancer, defined by its marked aggressiveness, is also recording significant advances. In this regard, it has pointed out that the addition of immunotherapy to chemotherapy has managed to improve survival in patients with extensive disease. “More recently, the development of bispecific antibodies capable of activating T lymphocytes against tumor cells has opened up a new therapeutic path,” it added.

The scientific society insists that these progress must be accompanied by policies that guarantee effective prevention, early detection, and equitable access to innovation for all patients with lung cancer.